Drug Profile
Research programme: cannabinoids - Peak Pharmaceuticals
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Cannabis Therapy Corp
- Developer Peak Pharmaceuticals
- Class Cannabinoids
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Aug 2018 No recent reports of development identified for research development in Inflammation in USA
- 19 Jan 2015 Cannabis Therapy Corp is now Peak Pharmaceuticals